Drugs / RG2077
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00076934 | Jan 2003 → Feb 2006 | relapsing-remitting multiple sclerosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RG2077 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00076934 ↗ |
| Known as | CTLA4-IgG4m | “RG2077 (CTLA4-IgG4m)” NCT00076934 ↗ |
| Action | Inhibit | “to block the CD28/B7 T-cell costimulatory pathway” PMID 18794494 ↗ Sep 2008 |
| Modality | Protein / enzyme biologic | “RG2077 (CTLA4-IgG4m)” NCT00076934 ↗ |
| Route | Intravenous | “We used IV infusions of CTLA4Ig” PMID 18794494 ↗ Sep 2008 |